Market Overview

Celator Shares Down ~5% Apparently Amid Earlier Report of Update to ClinicalTrials.gov CPX-351 Trial Status to 'Suspended'; National Institutes of Health Spokesperson Tells Benzinga That Update was Submitted Apr. 13

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News Exclusives

 

Related Articles (CPXX)